Immunologic Factors: all 3,292 studies that test it
Page 30 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple MyelomaCompletedNCT00305812Phase 2
- GM-CSF Before Surgery in Treating Patients With Localized Prostate CancerCompletedNCT00305669Phase 1
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaTerminatedNCT00301795Phase 2
- Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar PustulosisCompletedNCT00301002Phase 2
- Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)CompletedNCT00299819Phase 1
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerCompletedNCT00296023Not applicable
- Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency DiseaseCompletedNCT00295971Phase 1
- Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's DiseaseTerminatedNCT00295165Phase 3
- IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and MelanomaStatus unknownNCT00294476Phase 2
- Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix HexaCompletedNCT00294294Phase 4
- Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaStatus unknownNCT00293475Phase 1/2
- Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and VasculitisCompletedNCT00293072Phase 2
- Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell LymphomaCompletedNCT00290667Phase 2
- Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet TransplantationCompletedNCT00286624Phase 1/2
- Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 YearsCompletedNCT00285389Phase 2
- Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic LeukemiaTerminatedNCT00281931Phase 2
- Open Label Natalizumab Safety Extension Study for Subjects With Crohn's DiseaseCompletedNCT00280956Phase 4
- Rituximab in Combination With Outpatient Therapy for CD20+ LymphomaCompletedNCT00280878Phase 2
- Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyTerminatedNCT00279435Phase 2/3
- A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisTerminatedNCT00279422Phase 2/3
- Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00278421Phase 3
- Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-GlucanTerminatedNCT00276445Phase 4
- Open-Label Natalizumab Safety Extension StudyCompletedNCT00276172Phase 3
- Study Evaluating Prevenar Vaccine in Healthy InfantsCompletedNCT00276107Phase 4
- Pilot Study of Rituximab for Membranoproliferative GlomerulonephritisCompletedNCT00275613Phase 1
- Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaCompletedNCT00275054Phase 3
- Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00274989Phase 2
- VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHLCompletedNCT00274794Not applicable
- Subcutaneous Immunoglobulin Treatment for Multifocal Motor NeuropathyCompletedNCT00268788Phase 2
- Immunopharmacological Effects of Rituximab in Atopic DermatitisCompletedNCT00267826Not applicable
- Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's DiseaseCompletedNCT00267722Phase 2
- Visilizumab for Treatment of Perianal Fistulas in Crohn's DiseaseCompletedNCT00267709Phase 2
- Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative ColitisCompletedNCT00267306Phase 1/2
- Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaTerminatedNCT00265928Phase 2
- Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic LeukemiaTerminatedNCT00265915Phase 2
- Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell LymphomaStatus unknownNCT00261612Phase 2
- Rituximab Treatment to Block HLA Antibodies in Renal Transplant RecipientsWithdrawnNCT00261547Phase 1/2
- Rituximab in Active Ulcerative ColitisCompletedNCT00261118Phase 2/3
- RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal GammopathyCompletedNCT00259974Phase 3
- A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal EncephalitisCompletedNCT00259805Phase 1
- Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's LymphomaStatus unknownNCT00258336Phase 2
- Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV DrugsCompletedNCT00257127Not applicable
- Safety and Efficacy Study of Rituximab in Renal TransplantationCompletedNCT00255593Phase 1
- Lenalidomide and Docetaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00253344Phase 1
- Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular LymphomaCompletedNCT00251394Phase 2
- Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic PurpuraWithdrawnNCT00251277Phase 1/2
- Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's LymphomaTerminatedNCT00250861Phase 2
- Effectiveness of Rituximab in Pediatric OMS Patients.CompletedNCT00244361Phase 1/2
- Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.Status unknownNCT00244127Phase 2
- Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell LymphomaCompletedNCT00242996Phase 2
- Single Dose Thymoglobulin for Induction in Adult Renal Allograft RecipientsTerminatedNCT00235781Not applicable
- Safety and Tolerability of Repeat Courses of IM AlefaceptCompletedNCT00233662Phase 3
- Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)CompletedNCT00231439Phase 2/3
- IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell ImmunodeficiencyCompletedNCT00228852Phase 1/2
- Rituximab in Treating Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT00227695Phase 3
- To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity ConditioningWithdrawnNCT00226512Phase 3
- Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a SplenectomyTerminatedNCT00225875Phase 2
- Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsCompletedNCT00220766Phase 3
- Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New GuineaCompletedNCT00219401Phase 2
- Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic SyndromesCompletedNCT00217386Phase 2
- Safety Study of Rituximab (Rituxan®) in Chronic UrticariaTerminatedNCT00216762Phase 1/2
- Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaTerminatedNCT00216164Phase 2
- Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSKCompletedNCT00216034Phase 3
- A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal TransplantationCompletedNCT00214266Phase 2
- Effect of Anti CD20 in Pemphigus DeseaseCompletedNCT00213512Phase 2/3
- Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ TransplantsCompletedNCT00213265Phase 3
- Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's LymphomaCompletedNCT00210379Phase 2
- A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous MeningitisWithdrawnNCT00210340Phase 1
- Randomized Phase III Adjuvant Study for Stage III Colorectal CancerStatus unknownNCT00209742Phase 3
- Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With SargramostimTerminatedNCT00206713Phase 3
- Open-label Trial of Leukine in Active Crohn's DiseaseTerminatedNCT00206700Phase 2
- Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00206674Phase 3
- Safety and Efficacy Study in the Treatment of Pediatric Crohn's DiseaseTerminatedNCT00206661Phase 1/2
- Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's DiseaseCompletedNCT00206596Phase 2
- Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00204659Phase 2
- Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic LeukemiaCompletedNCT00201721Phase 2
- Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT00201682Phase 1/2
- Safety Study of Radio-labeled huA33 Antibody in Colorectal CancerCompletedNCT00199862Not applicable
- Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in AdultsCompletedNCT00199082Phase 4
- Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and RituximabCompletedNCT00199004Phase 4
- German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00198978Phase 4
- Intravenous Immune Globulin to Treat Hereditary Inclusion Body MyopathyCompletedNCT00195637Phase 1
- Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00193466Phase 2
- Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's LymphomaCompletedNCT00193440Phase 2
- Effect of Two Versus Three Pneumococcal Conjugate VaccinationsCompletedNCT00189020Phase 3
- Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)CompletedNCT00188136Phase 2
- Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell DiseaseCompletedNCT00186810Phase 2
- Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell LymphomaTerminatedNCT00183989Phase 2
- Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALLTerminatedNCT00180895Phase 2
- LMBA02 Protocol for Patients With a Burkitt LymphomaStatus unknownNCT00180882Phase 3
- A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the PancreasTerminatedNCT00179751Phase 1/2
- A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.TerminatedNCT00179738Phase 2
- Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaTerminatedNCT00179725Phase 1/2
- Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNCT00179712Phase 1/2
- Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung CancerTerminatedNCT00179699Phase 1
- A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung CancerCompletedNCT00179686Phase 2
- Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic ChemotherapyCompletedNCT00179608Phase 1
- Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseTerminatedNCT00176475Phase 1